<DOC>
	<DOCNO>NCT02033109</DOCNO>
	<brief_summary>This Phase 1 clinical trial evaluate MIV-150 , third generation non-nucleoside reverse transcriptase inhibitor , co-formulated potentially potent agent , zinc acetate prevention HIV infection woman . This first in-human PC-1005 ( MIV-150/zinc acetate carrageenan gel ) , first study female expose MIV-150 , first time MIV-150 administer topically , first time MIV-150 administer intravaginally .</brief_summary>
	<brief_title>Safety , Pharmacokinetics Acceptability PC-1005 Vaginal Use</brief_title>
	<detailed_description>This study begin safety run-in , open label , single-arm safety run-in 5 woman receive PC-1005 daily 3 consecutive day . Safety pharmacokinetics take place dose . participant run-in eligible main study . The main study participant randomize 4:1 study gel : 24 randomize PC-1005 ( active ) 6 randomize HEC gel ( placebo ) . The study product apply vaginally daily 14 day clinical laboratory assessment baseline ( enrollment ) 1st , 2nd , 8th , 9th , 14th dos , safety follow-up visit 7 day 14th dose . Participants run-in main study request sexually abstinent start immediately Screening Visit study exit .</detailed_description>
	<criteria>Women 19 49 year age , inclusive Willing able provide write informed consent Healthy , base medical history , vital sign , physical examination , urinalysis , laboratory evaluation genital infection laboratory evaluation hematology , liver renal function BMI ≥18 kg/m^2 ≤32 kg/m^2 HIVnegative determine HIV ELISA test screen Hepatitis B C negative screening Rapid plasma reagin negative screening If HSV2 positive , must free outbreak least 6 month prior screen In absence use exogenous hormone ( ) , selfreported regular menstrual cycle , define minimum 21 day maximum 35 day menses Normal Pap test screening Agrees use one form effective contraception duration trial Willing abstain sexual intercourse/activity include receptive vaginal , oral , digital , anal intercourse , use vaginal product include tampon , male female condom , contraceptive sponge , diaphragm , cervical cap , douche , lubricant , vibrators/dildos start Screening Visit Study Exit Agrees participate clinical research trial duration trial History know sensitivity/allergy component either study product Currently pregnant breastfeeding , within 3 month last pregnancy outcome Participation clinical research trial involve investigational market product currently within two month participation prior screening , include trial spermicide , microbicide and/or drug Diagnosed treat STI ( HSV ) pelvic inflammatory disease last 3 month Positive test Neisseria gonorrhea , Chlamydia trachomatis , Trichomonas vaginalis Symptomatic vulvovaginal candidiasis , bacterial vaginosis ( BV ) , urinary tract infection ( UTI ) screen Presence clinically significant genital epithelial finding abrasion , ulceration , laceration , vesicle suspicious STIs screen Presence clinically significant abnormal physical finding vulva , vaginal wall cervix screen Any clinically significant abnormal hematology , chemistry urinalysis finding screen Any chronic ( exclude HSV2 ) progressive disease ( include know history cancer , diabetes , cardiac disease , autoimmune disease , blood dyscrasia , Wilson 's disease ) , sign cardiovascular disease , renal failure , even control medication History hysterectomy menopause Use exclude contraceptive method include Nuvaring® , condom ( male female ) , contraceptive sponge , diaphragm , cervical cap ( Safety Runin Main study ) History gynecological surgery procedure within past 2 month History uterine prolapse , undiagnosed vaginal bleeding urethral obstruction within last 3 month , include breakthrough bleed require sanitary protection Known current drug abuse , include illicit drug , alcohol abuse Any condition ( ) , opinion Investigator , might interfere adherence trial requirement evaluation trial objective Unable comply study requirement , include limited , attend study visit , use gel direct , observe abstinence throughout study use effective contraceptive , limit alcoholic beverage 2 per day caffeine 6 serving per day History latex allergy</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>